Treatment of Gancyclovir Resistant Cytomegalovirus with Foscarnet: a Report of Two Cases Occurring After Bone Marrow Transplantation
Authors:
- 1 January 1994
- journal article
- case report
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 12 (5-6) , 477-480
Abstract
Cytomegalovirus (CMV) infection is common in patients who undergo allogeneic bone marrow transplantation. Gancyclovir is useful in treating CMV infections. Resistance to gancyclovir is rare and has, thus far, not been reported in the setting of BMT. Two patients with CMV infections unresponsive to gancyclovir were successfully treated with foscarnet. 10-15% of CMV infections are resistant initially or develop resistance to gancyclovir. Both patients had an adequate trial of gancyclovir and resistance developed over time. While we did not document resistance in the laboratory there was dramatic clinical improvement with foscarnet.Keywords
This publication has 4 references indexed in Scilit:
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991
- Cytomegalovirus Infection in Patients with AIDSThe Journal of Infectious Diseases, 1988
- Nonbacterial Pneumonia After Allogeneic Marrow Transplantation: A Review of Ten Years' ExperienceClinical Infectious Diseases, 1982
- A RANDOMISED TRIAL OF ORAL GAMMAGLOBULIN IN LOW-BIRTH-WEIGHT INFANTS INFECTED WITH ROTAVIRUSThe Lancet, 1982